RAI - search results

If you're not happy with the results, please do another search

0 648
Marijuana-Stocks-brain weed

Investigative research on medical marijuana has been extraordinary for the culture and the medical benefits of cannabis have truly been taking off. Yet another study has confirmed that cannabinoids are more effective in reducing the frequency of an acute migraine headache pain than currently prescribed medication. And, naturally, there are far fewer side effects.

What’s Involved In Marijuana Research?

The study, which included 127 participants who suffered from chronic migraine and cluster headaches, which are severe headaches that occur on one side of the head usually around one eye. Migraine pain usually affects both sides of the head and is often accompanied by sensitivity to light, visual distortions and nausea.

The researchers, who presented their findings at the 3rd Congress of the European Academy of Neurology in Amsterdam, gave study participants a cannabis-based medication that was a combination of THC and CBD. The study, led by Dr. Maria Nicolodi and published in the European Pharmaceutical Review, was done in two phases.

In the first phase, sufferers of chronic, acute migraines were given varying doses of the THC-CBD combination. The results showed that those who received 200 mg doses each day for three months experienced significantly less pain—about 55 percent less—while lower doses did not provide the same pain relief.

The second phase included both those suffering from chronic migraines and those suffering from cluster headaches. Migraine sufferers were given either the THC-CBD treatment or 25 milligrams of amitriptyline, an antidepressant often used to treat migraines.

The cluster headache sufferers were given either the THC-CBD treatment or 80 milligrams of verapamil, a calcium channel blocker often prescribed for cluster headaches. The results showed that THC-CBD was slightly better at reducing the frequency of migraine attacks than the commonly prescribed medications.

The THC-CBD combination was very effective at reducing migraine pain, cutting it by 43.5 percent. It was also effective at reducing the severity of pain among cluster headache sufferers, but only if they had a history of migraines from childhood. The study reinforces earlier research showing that medical marijuana is effective in reducing the frequency of migraines.

In reference to the Migraine Research Foundation, migraine headaches are the third most prevalent illness across the globe, affecting around one billion people, making it the sixth most disabling illness in the world.

Amazingly, 12 percent of the population in the United States (more than 38 million people) suffer from migraines and that includes children, who often go undiagnosed. So, when your children complain of bad headaches, pay attention.

Nicolodi’s study is yet another research finding that confirms MMJ to be an effective and far safer alternative to prescription pain medications. In view of the rush to prescribe opioids and other prescription drugs, which currently has millions of Americans addicted, dying from overdoses or incarcerated, isn’t it time to start looking at safe alternatives?


80,000 Chill Gummies Sold as a Result of Highly Productive PotNetwork Road Show


PotNetwork Holding, Inc. (OTC Pink: POTN) announced today that the Company’s subsidiary, Diamond CBD, has entirely sold out of its increasingly popular proprietary Chill Gummy line.

The past six months of trade show, expo, and convention attendance have demonstrated Management’s determined commitment to achieve strong results, yielding in product demand requiring significant expansion of its manufacturing operations. The Company’s Chill Gummy inventory is slated to be restocked within approximately two weeks.



Click Here Now To Read (POTN) Release

Investing in Cannabis is a No-Brainer


This past Thursday a new bill was passed that would effectively end the prohibition on the use of medicinal cannabis. While it was certainly a happy occasion to note the bipartisan effort put in, it is also frustrating to most to still have the struggle behind legalization. To have the amount of pushback against legislation in favor of a plant that has the ability to help many, is asinine to the majority of the public’s opinion.


Click Here Now To Read Full Article



How Florida’s Medical Marijuana Will Change Under Proposed Rules

Health officials in the state of Florida have issued new rules to be implemented within the state’s constitutional medical marijuana amendment.

The regulations that were shown to the public on Friday by the Department of Health use the same framework as a bill passed on June ninth by the State Legislature during a special session. Last month, the department showed an outline to the public where it would give a fifteen days notice before they decided to put into play any new rules with the public having three days to submit feedback.


Click Here Now To Read Full Article

0 3727

This past Thursday a new bill was passed that would effectively end the prohibition on the use of medicinal cannabis. While it was certainly a happy occasion to note the bipartisan effort put in, it is also frustrating to most to still have the struggle behind legalization. To have the amount of pushback against legislation in favor of a plant that has the ability to help many, is asinine to the majority of the public’s opinion.

Many beg the question, why do we need permission to use treatment that works the best for various illnesses? It seems to be a clear violation of the laws and rights surrounding personal sovereignty, but that ceases to bother Attorney General Jeff Sessions who essentially asked congress for the permission to prosecute those involved with medicinal cannabis.

Jeff Sessions is notably in disbelief of cannabis as a medicine and continuously disregards patients stories of how the wonder-drug has helped them.

A woman named Charlotte Figi was diagnosed with a severe case of epilepsy at an early age. By the age of three, Figi was having around three-hundred seizures per week. A miserable existence for such a young girl. All of the conventional forms of treatment failed to work.

Charlottes parents were desperate for relief for their child and had heard of another child with a similar medical diagnosis using medicinal cannabis to cure his condition.

As soon as they heard, they got ahold of the medicine and began giving it to Charlotte. Almost instantly her symptoms improved. Today, Charlotte has very few seizures all thanks to the help of medicinal cannabis. Those who developed the specific strain of cannabis with little to no incidence of psycho activity in the drug, appropriately named their strain, Charlotte’s web. Today that strain has helped many children to treat their conditions without the worry of getting high.

Aside from this, there has been several instances of medical cannabis improving the lives of people wit conditions across the board.

So why invest in cannabis? As a direct result of our capitalist agenda, the freedom to impart positive change through a free market without the threat of violence is one of the most powerful ways to start a movement. Because of this, the dangers involved in investing in cannabis stay at a constant level.

In addition to its safety, the main attraction is that investing in marijuana is incredibly profitable. As a new industry on the rise, the potential for monetary gain is as high as ever.

Last year, sales from cannabis hit over a staggering twenty billion dollars, with an annual growth rate of twenty-five percent. This is expected to only get higher and is surpassing the growth rate of the famed dot-com era.

The bottom line lies in the fact that when an industry has this much potential it is difficult for it to lean towards a downtrend at any time. This would be especially difficult for someone like Attorney General Jeff Sessions to shut down.

Because of this and many other reasons, medicinal cannabis remains one of the highest rated, highest increasing and admittedly the most moral investment that one can make.

0 2056
Marijuana-Stocks-Cannais On The Brain

Marijuana is most commonly known as a combination of the dried buds found in the Cannabis Sativa plant. There are many ways of using the plant such as eating, vaporizing, smoking, brewed, and tons more, however the most common method remains smoking the plant in some sort of pipe-like device.

The chemical that provides for that intoxicating fuzzy-feeling is called tetrahydrocannabinol, or THC. This chemical reacts with various neurotransmitters within our brain to produce the high we feel when we use marijuana. The average THC content of marijuana has soared from less than one percent in the early seventies, all the way to nearly thirteen percent in the past five to ten years. Some marijuana has been reported to reach THC levels of nearly thirty percent.

A recent poll found that one in eight people smoked marijuana regularly while forty three percent of U.S. adults have admitted to trying it. These numbers have steadily increased throughout the past fifty years and remain on the rise with the legalization of the plant.

Marijuana reacts with several of the same pleasure-chemical centers in the brain that can be targeted by other drugs such as heroin, cocaine, and alcohol. Marijuana can produce a feeling of euphoria, or what most refer to as the “high” which is strengthened or weakened depending on the quantity, quality and method of consumption. When smoking as opposed to other methods, the high is stimulated in the brain almost instantly. This is because our brain is naturally wired to receive and break down THC. After smoking, many report a feeling of overwhelming calmness and strengthened sensory perception. This is followed by an altered perception of appetite leading the user to get what is referred to commonly as the “muchies”.

Although marijuana use through smoking can cause similar respiratory problems experienced by tobacco smokers, the incidence of more serious diseases such as cancer and asthma remains low.

A recent study found that there may be a link between genetics and marijuana use. This suggests that some may have a predisposition for the drug which may or may not lead to addiction.

Marijuana has many amazing benefits and little to argue against it. With the country and world legalizing the plant and becoming more and more comfortable with recognizing its health benefits, the world of cannabis will only continue to grow.

0 1516

According to a report from the Los Angeles Times, California is gearing up to launch a legal cannabis trade that is expected to boost the state’s economy up to five billion dollars.

The article, which is based on a study of the University of California Agricultural Issues Center, states that while the newest version of a cannabis industry will undoubtedly increase revenues to an impressive amount. Obviously, it will take some time before the entire cannabis community is on board with a fully legalized system.

The study states that thirty percent of the state’s marijuana buyers will still frequent the black market so that they can avoid paying the steep taxes and costs associated with the legal marijuana industry.

The gap between the legal and illegal market is expected to close as it did after the prohibition of alcohol.

The director of the state Bureau of Marijuana Control, Lori Ajax, stated that “It’s going to take some time. While it’s unlikely that everyone will come into the regulated market on day one, we plan to continue working with stakeholders as we move forward to increase participation over time.”

Still, right off the bat, more than sixty percent of the state’s medical marijuana buyers will become completely legitimate within the next few months.

Unfortunately for the medical marijuana industry in the state, recreational cannabis is on the rise.

The study shows that only nine percent of the state will continue to buy medical marijuana post recreational.

Researchers are anticipating that the medicinal sector will take an enormous hit plunging from two billion to around six hundred million dollars, as adults reach the age of twenty-one where they can legally purchase recreational marijuana.

This factor has researchers believing that California will soon be a hotspot for a one hundred and seventeen billion dollar tourism trade— possibly becoming the largest state in the nation for tourism related to legal marijuana.

0 644
marijuana stocks

Lexaria raises US$1M from Warrant Exercise

“Lexaria’s balance sheet is now the strongest it has ever been,” commented Chris Bunka, CEO. “We have raised over US$3 million in the past six months, which fully funds the Company’s business plans until 2019. We are now focussed on developing our patent portfolio and continuing our work with prospective licensees and resellers.”

Following issuance of these common shares, Lexaria will have 66,506,009 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds will be used for general corporate purposes. Lexaria extends its thanks to its loyal shareholders for their continued support.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria
Lexaria Bioscience Corp is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.


This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods and ViPova™ products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

0 1650
Marijuana-Stocks-Cannais On The Brain

Here’s some counterintuitive news for those who have been hammered all their lives with claims that cannabis causes memory loss.

A new study by scientists at the University of Bonn, written up in the journal Nature Medicine, found that aging mice treated with daily small doses of THC actually experienced a reversal of cognitive decline. That is, they started doing better on cognitive tasks, such as going through a maze.

The researchers foresee potential cannabis-based treatment to fend off dementia.

“If we can rejuvenate the brain so that everybody gets five to 10 more years without needing extra care, then that is more than we could have imagined,” said study leader Andras Bilkei-Gorzo.

The bad news for stoners is that the study found that the THC applications had the reverse effect in young mice—hindering their cognitive capabilities.

But it will be interesting to see what kind of media splash this makes. So far, the study has been written up in the Guardian but has mostly been covered by niche sites like Medical XPress and Popular Science.

In February 2016, when a study from researchers at Switzerland’s University of Lausanne found a link between years of daily cannabis use and a middle-age decline in short-term memory (as measured in verbal skills), it was written up in the Washington Post. We’ll see if WaPo now covers the new findings.

And in January 2016, University College London researchers found no impact of cannabis on the IQ of young users. The IQs of young cannabis users and non-users was virtually identical. These findings were noted in Science magazine but failed to win much mainstream coverage.

Back in July 2011, Time magazine did allow a guest editorial by Maia Szalavitz on a study that followed 2,000 Australians through young adulthood, finding no difference in cognitive abilities between cannabis users and non-users.

0 508

22nd Century Raises 2017 Revenue Projection to $16Million – Another Record Year

22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company, announced today that the Company’s wholly-owned subsidiary, NASCO Products, recently entered into substantial new manufacturing agreements for the production of filtered cigars and other tobacco products. The products to be manufactured by 22nd Century as a result of these executed new contracts are currently supplied to more than 250 distributors and wholesalers and more than 40,000 retail stores across the United States.

In order to accommodate this sizeable increase in business, 22nd Century has already hired 37 new employees, more than doubling its workforce at the Company’s NASCO factory in Mocksville, North Carolina. When combined with existing business, 22nd Century is raising its 2017 total revenue projection from a previously announced $12,000,000 to more than $16,000,000. In 2018, 22nd Century anticipates total revenues will significantly exceed $20,000,000 and the Company’s factory will be cash flow positive.

“Our manufacturing facility is a vital strategic asset for 22nd Century Group,” explained Henry Sicignano, III, President and Chief Executive Officer at 22nd Century. “The factory enables 22nd Century to develop and manufacture the Company’s SPECTRUM® government research cigarettes, our X-22 smoking cessation cigarettes in development, and 22nd Century’s proprietary MRTP candidates: BRAND A Very Low Nicotine cigarettes, and BRAND B low tar-to-nicotine ratio cigarettes. Now, considering the newly signed contract manufacturing agreements, our NASCO production facility will also contribute positively to 22nd Century’s bottom line.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking. The Company’s primary mission in cannabis is to develop proprietary cannabis strains for important new medicines and agricultural crops. Visit and for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 8, 2017, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

View source version on

0 137

In the near future, a new medical device may be fighting cancer; specifically combating glioblastoma, the most aggressive cancer that begins in the brain. The “electric cap” is a device that zaps tumors with electrical currents with the hopes of boosting survival in patients with the deadly form of cancer.

According to the researchers and developers of the new device, the “electrical cap,” formally called Optune, is worn on the head and exposes the cancer cells to a rapidly alternating sequence of low-intensity electrical frequencies, thereby interrupting the cancer cell’s ability to function. Study author Dr. Roger Stupp, a professor of neurological surgery at Northwestern University’s Feinberg School of Medicine in Chicago said, “The cap is an entirely different way to treat cancer.”

It is critical to note that this device is still in the beginning phases of development. It currently stands as a proof of concept that the treatment modality actually works to prevent tumor cells from growing and dividing. Doctor Stupp says that the device does increase the survival rates by a substantial amount. The cap is the first treatment to improve overall results in over a decade.

The introduction of this device is definitely welcome, as the current standard of care for treatment of glioblastomas often includes a lengthy combination of surgery, radiation therapy, and chemotherapy, and only offers a roughly 27% chance of survival two years after diagnosis. But with the addition of this device to current treatment, researchers hope to achieve better results.

Optune achieves results by disrupting cancer cell division and therefore inducing cancer cell death. The concept was tested among a pool of nearly 700 patients with glioblastoma between 2009 and 2014. Some of the patients in this group were treated with standard care methods while others were given standard care plus the electric cap. At the end of the trial, the team found that the standard care patient’s survival time averaged 16 months, while those who used the electric cap in combination with standard therapy saw an average 21-month survival time.

Truly promising early results, as typical survival rates for the standard of care treatment at two, three, four, and five years are approximately 32%, 16%, 8%, and 5%. However, when compared to the introduction of the cap into the mix, survival rates for the same periods reached 43%, 26%, 20%, and 13%. By merging all the data gathered, the researchers concluded that cap patients had a 37% lower overall risk of death when compared to patients who only received standard care. While this may signify a new frontier in the field of brain cancer treatment, Dr. Stupp noted that this form of treatment will not work in fighting all cancers.

0 98

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
Ad Placements